<SEC-DOCUMENT>0001193125-26-091436.txt : 20260304
<SEC-HEADER>0001193125-26-091436.hdr.sgml : 20260304
<ACCEPTANCE-DATETIME>20260304160002
ACCESSION NUMBER:		0001193125-26-091436
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260302
FILED AS OF DATE:		20260304
DATE AS OF CHANGE:		20260304

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Mazzariello Gina
		CENTRAL INDEX KEY:			0001913765
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41199
		FILM NUMBER:		26721032

	MAIL ADDRESS:	
		STREET 1:		C/O AMYLYX PHARMACEUTICALS, INC.
		STREET 2:		43 THORNDIKE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amylyx Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001658551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464600503
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		55 CAMBRIDGE PARKWAY
		STREET 2:		SUITE 6W
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-682-0917

	MAIL ADDRESS:	
		STREET 1:		55 CAMBRIDGE PARKWAY
		STREET 2:		SUITE 6W
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-03-02</periodOfReport>

    <notSubjectToSection16>false</notSubjectToSection16>

    <issuer>
        <issuerCik>0001658551</issuerCik>
        <issuerName>Amylyx Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>AMLX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001913765</rptOwnerCik>
            <rptOwnerName>Mazzariello Gina</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O AMYLYX PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>55 CAMBRIDGE PARKWAY, SUITE 6W</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Legal Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2026-03-02</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>6844</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>14.5205</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>134430</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.400 to $15.070. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Joshua B. Cohen, as Attorney in Fact</signatureName>
        <signatureDate>2026-03-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
